Market News & Trends
Ocular Therapeutix Achieves Target Randomization of 555 Subjects in SOL-R
Ocular Therapeutix, Inc. recently announced that its SOL-R registrational trial of AXPAXLI™ (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD) has achieved…
Argonaut Manufacturing Services Appoints Rick Hancock as CEO to Lead Next Phase of Growth
Argonaut Manufacturing Services recently announced the appointment of Rick Hancock as Chief Executive Officer (CEO). Rick is a biotechnology executive with more than 40 years…
Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, Into IND-Enabling Studies
Enara Bio recently will unveil its newly discovered cancer-specific target DARKFOX as the first in a new category of validated Dark Antigens in an oral…
Eder Therapeutics & XCubeBio Partner to Establish Joint NewCo for Global Development & Future Market Entry Activities
Eder Therapeutics, a Canadian biopharmaceutical company focused on rare genetic disorders and XCubeBio AG, a biotechnology platform company focused on accelerating successful international market entry…
Rein Therapeutics Receives FDA Clearance to Resume Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics recently announced the US FDA has lifted the full clinical hold on the Company’s Phase 2 “RENEW” trial evaluating LTI-03 in patients with…
InterCure & Cannasoul Sign Strategic Investment & Collaboration Agreements to Advance Cannabis Science & Pharmaceutical Innovation
InterCure Ltd. recently announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd. (“Cannasoul”), a globally recognized…
Trelleborg Expands Biopharmaceutical Manufacturing Capabilities in US
Trelleborg Medical Solutions announces the grand opening of its expanded manufacturing facility and BioPharma Center of Excellence in Northborough, Massachusetts, driving its strategy for growth…
Piramal Pharma Solutions Formalizes Partnership With IntoCell, Expanding its Payload-Linker Platform & Bioconjugate Capabilities
Piramal Pharma Solutions has signed a Memorandum of Understanding (MOU) to solidify its strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc.…
4DMT Announces Exclusive License Agreement With Otsuka Pharmaceutical for Development & Commercialization of 4D-150 in Asia-Pacific
4D Molecular Therapeutics recently announced a strategic partnership with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to develop and commercialize 4D-150 for the treatment of wet age-related…
Clearmind Medicine Advances Fight Against Cocaine Addiction With Publication of US Patent Application for its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Clearmind Medicine Inc. recently announced the publication of a US patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of…
Zag Bio Launches With $80 Million Financing to Advance Thymus-Targeted Medicines for Autoimmune Diseases
Zag Bio, Inc. recently announced the company’s launch with $80 million in financing, including a recently closed Series A financing. Polaris Partners founded and incubated Zag…
Slingshot Biosciences & Cellares Combine TruCytes Biomarker Controls With Cell Q Platform to Enhance Quality & Automation in Cell Therapy Manufacturing
Slingshot Biosciences recently announced a strategic collaboration with Cellares that integrates Slingshot’s TruCytes Biomarker controls into Cellares’ Cell Q, the industry’s first fully automated quality-control…
Olympia Pharmaceuticals Strengthens National Presence, Bringing New Licensing to Mississippi
Olympia Pharmaceuticals recently announced its expansion into Mississippi after successfully obtaining licensing in the state. This is a significant step in its goal to support…
Zenas BioPharma Announces Positive Results From Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Zenas BioPharma, Inc. recently announced positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS). Obexelimab met the primary endpoint,…
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today presented new preclinical data…
NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination With a GLP-1 Receptor Agonist
NodThera, a clinical-stage biotech pioneering a paradigm shift in the treatment of chronic inflammatory diseases through NLRP3 inhibition, today announced that the first patients have…
Curia Invests $4 Million to Enhance Sterile API Manufacturing
Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its two…
Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities & OpenAI Strategic Collaboration at CPHI Frankfurt 2025
Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest flexible solutions to help boost efficiency and scale in biopharmaceutical manufacturing…
Sharp Services Invests $100 Million in US & European Facilities to Increase Capacity & Service Offerings
Sharp Services, a leader in pharmaceutical packaging, clinical trial services & sterile manufacturing has announced a $100 million investment across its global facility network to…
Serán BioScience Expands Commercial Manufacturing With New Campus in Bend, Oregon
Serán BioScience, LLC, a leading science-driven drug development partner, today announced the completion of two of the three new buildings and commencement of construction of…
